Zimbabwe made history by becoming the first country in Africa — and only the third in the world — to approve cabotegravir (CAB-LA), a long-acting injectable drug that significantly reduces HIV transmission. The World Health Organization called the move a “crucial step” and pledged to help Zimbabwe roll out programs to make CAB-LA as widely available and effective as possible.
At a glance
- CAB-LA approval: Zimbabwe joined Australia and the U.S. as the only countries to have approved the injectable drug, which the WHO recommended in July 2022 C.E. as highly effective at reducing HIV transmission among people at greatest risk.
- HIV prevention progress: AIDS-related deaths in Zimbabwe have fallen from an estimated 130,000 in 2002 C.E. to just 20,000 in 2021 C.E. — a reduction of more than 84% in less than two decades.
- 90-90-90 milestone: Zimbabwe already achieved the UNAIDS 90-90-90 target: 90% of people living with HIV know their status, 90% are on antiretroviral treatment, and 90% have the virus suppressed.
Why this drug matters
CAB-LA works differently from daily oral HIV prevention pills. Given as an injection every two months, it removes the burden of daily adherence — a major barrier for many people, particularly young women and girls in sub-Saharan Africa.
That matters enormously in Zimbabwe and across the region, where women and girls bear a disproportionate share of new HIV infections. Oral pre-exposure prophylaxis (PrEP) has existed for years, but daily pill regimens can be difficult to sustain in settings where stigma, privacy concerns, and inconsistent healthcare access all work against consistent use.
The WHO’s July 2022 C.E. recommendation described CAB-LA as highly effective for people at substantial risk of contracting HIV — a category that includes sex workers, men who have sex with men, and young women in high-prevalence areas. Zimbabwe’s rapid regulatory action translated that global guidance into national policy faster than any other African nation.
Voices from the ground
Nyasha Sithole, of the Development Agenda for Girls and Women in Africa (DAWA) network, captured the significance plainly. “Accelerating HIV prevention for girls and young women requires an expansion of choices available,” she said. “I am excited and proud to know that my own country has approved the use of CAB-LA. This will contribute to our basket of HIV prevention tools that work for us as girls and women in Zimbabwe.”
Her framing — a “basket of tools” — points to something important. No single intervention ends an epidemic. Zimbabwe’s success so far has come from layering strategies: testing, treatment, suppression targets, and now an expanded prevention toolkit.
Hard-won progress, but real obstacles remain
Zimbabwe’s HIV response is one of the more remarkable public health turnarounds on the continent. In the late 1990s and early 2000s C.E., the country had one of the highest HIV prevalence rates in the world. Community-level treatment programs, international partnerships, and sustained political commitment drove that 84% decline in AIDS-related deaths over roughly two decades.
In 2021 C.E., Zimbabwe also launched a national strategic plan to end AIDS by 2030 C.E., aligning with global targets. UNAIDS data show the country is one of only a handful in sub-Saharan Africa to have hit all three 90-90-90 benchmarks — a genuine achievement in a region still carrying the heaviest HIV burden in the world.
The path from approval to access, however, is rarely simple. Getting newly approved drugs to the people who need them most — especially in low- and middle-income countries — involves procurement, supply chains, trained healthcare workers, and community trust. Zimbabwe’s healthcare system is under severe strain from an ongoing economic crisis, and no one at the Ministry of Health was available to comment at the time of the announcement. Those structural pressures are real and cannot be wished away.
The WHO’s commitment to support Zimbabwe in designing and implementing CAB-LA programs is a meaningful pledge, but implementation will take time, resources, and sustained coordination between government, global health bodies, and local communities. The approval is the beginning of a process, not the end of one.
A signal for the continent
Zimbabwe’s decision may carry weight beyond its own borders. Regulatory approval by a country with deep HIV experience and an established national AIDS strategy sends a signal to health authorities across Africa that CAB-LA is both safe and worth prioritizing. Médecins Sans Frontières and other access advocates have argued for years that Africa should not be last in line for life-saving HIV interventions approved elsewhere.
With roughly 25 million people living with HIV in sub-Saharan Africa — more than two-thirds of the global total — the region’s regulators moving quickly on evidence-based tools is not just symbolically important. It is a practical matter of lives.
Zimbabwe’s first-mover status in Africa on CAB-LA approval is a small but concrete piece of that larger effort.
Read more
For more on this story, see: The Guardian
For more from Good News for Humankind, see:
- Alzheimer’s risk cut in half by drug in landmark prevention trial
- U.K. cancer death rates down to their lowest level on record
- The Good News for Humankind archive on Zimbabwe
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More Good News
-
Romania finally recognizes trans man’s identity in landmark E.U. victory
Romanian trans rights took a real leap forward this week, as courts finally ordered the government to legally recognize Arian Mirzarafie-Ahi as male — a recognition the U.K. granted him back in 2020. For years, he lived with two identities depending on which border he crossed, until his case climbed all the way to the E.U.’s top court and came home with a binding answer. That ruling now obligates every E.U. member state to honor gender recognition documents issued by another. It’s a quiet but powerful shift: transgender people across Europe gain stronger footing not through new laws, but through…
-
Alaska judge permanently shields Tongass old-growth forests from logging
The Tongass National Forest just won a major day in court, with a federal judge ruling in March 2026 that the U.S. Forest Service is not legally required to ramp up logging to meet timber industry demand. The decision protects the world’s largest temperate old-growth rainforest — home to roughly a third of what remains of this ecosystem globally, along with wild salmon runs, brown bears, and trees older than 800 years. Tribal nations, fishing crews, and tourism operators stood alongside federal defenders in the case, a reminder that the forest’s value reaches far beyond timber. Wins like this give…
-
China plans to double its already massive clean energy supply by 2035
China’s new climate pledge to the United Nations sets a target of 3,600 gigawatts of wind and solar power by 2035 — more than the entire electricity-generating capacity of the United States today, and roughly double what China has already built. The commitment is woven into the country’s next Five-Year Plan, which directs state banks, provinces, and manufacturers to move in the same direction. Because China makes about 80% of the world’s solar panels, every factory it scales up makes clean energy cheaper for buyers in Africa, Southeast Asia, Latin America, and everywhere else. That ripple effect is what makes…
